Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors
CA Cancer J Clin. 2024 Apr 29. doi: 10.3322/caac.21840. Online ahead of print.ABSTRACTThe American Joint Committee on Cancer (AJCC) staging system for all cancer sites, including gastroenteropancreatic neuroendocrine tumors (GEP-NETs), is meant to be dynamic, requiring periodic updates to optimize AJCC staging definitions. This entails the collaboration of experts charged with evaluating new evidence that supports changes to each staging system. GEP-NETs are the second most prevalent neoplasm of gastrointestinal origin after colorectal cancer. Since publication of the AJCC eighth edition, the World Health Organization has updated the classification and separates grade 3 GEP-NETs from poorly differentiated neuroendocrine carcinoma. In addition, because of major advancements in diagnostic and therapeutic technologies for GEP-NETs, AJCC version 9 advocates against the use of serum chromogranin A for the diagnosis and monitoring of GEP-NETs. Furthermore, AJCC version 9 recognizes the increasing role of endoscopy and endoscopic resection in the diagnosis and management of NETs, particularly in the stomach, duodenum, and colorectum. Finally, T1NXM0 has been added to stage I in these disease sites as well as in the appendix.PMID:38685134 | DOI:10.3322/caac.21840
Source: Clinical Colorectal Cancer - Category: Cancer & Oncology Authors: Aman Chauhan Kelley Chan Thorvardur R Halfdanarson Andrew M Bellizzi Guido Rindi Dermot O'Toole Phillip S Ge Dhanpat Jain Arvind Dasari Daniel A Anaya Emily Bergsland Erik Mittra Alice C Wei Thomas A Hope Ayse T Kendi Samantha M Thomas Sherlonda Flem Jame Source Type: research
More News: Appendicitis | Brain | Cancer | Cancer & Oncology | Carcinoma | Colorectal Cancer | Endoscopy | Gastric (Stomach) Cancer | Gastroenterology | International Medicine & Public Health | Neurology | WHO